Biotech News

Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company

Cyclerion (CYCN)Cyclerion2025-09-23 20:01 ESTClinical readout

– Cyclerion Relaunches, Advancing a Phase 2–Ready Program for Millions Living with Treatment-Resistant Depression Through MIT License Agreement – – Webcast to be held September 24, 2025 at 10:30 a.m. ET – CAMBRIDGE, Mass. , Sept. 23, 2025 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc.

Open original release

Related news

AXSMAxsome2026-07-07 11:00 EST

Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)

KTTAPasithea Therapeutics2026-06-16 11:00 EST

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial

GHRSGH Research2026-06-04 11:00 EST

GH Research Announces Publication of Phase 2a Postpartum Depression Results

BTAIBioXcel2026-05-28 11:00 EST

BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting

DNLIDenali Therapeutics2026-05-21 22:00 EST

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

OGENOragenics2026-05-05 12:30 EST

Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.

BTAIBioXcel2026-04-08 11:00 EST

BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions

CYCNCyclerion2026-04-01 11:05 EST

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

NERVMinerva Neuroscience2026-03-31 20:05 EST

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

NERVMinerva Neuroscience2026-03-25 20:05 EST

Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

View all latest news

Cyclerion

Cyclerion was a biotechnology company focused on cyclic nucleotide biology and central nervous system or vascular-related disease programs before becoming a historical ticker. Its story reflected the challenge of turning a mechanistic platform into a durable drug franchise.

Recent company news

CYCNCyclerion2026-04-01 11:05 EST

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

CYCNCyclerion2026-02-17 12:00 EST

Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

CYCNCyclerion2026-01-05 21:01 EST

Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression

CYCNCyclerion2025-09-23 20:01 EST

Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company

CYCNCyclerion2024-12-17 13:08 EST

Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

Stock data

Close: 3.50 USD
Market cap: 13.08M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States